Search Results - "Sai, Hong"

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer by Peters, Solange, Camidge, D. Ross, Shaw, Alice T, Gadgeel, Shirish, Ahn, Jin S, Kim, Dong-Wan, Ou, Sai-Hong I, Pérol, Maurice, Dziadziuszko, Rafal, Rosell, Rafael, Zeaiter, Ali, Mitry, Emmanuel, Golding, Sophie, Balas, Bogdana, Noe, Johannes, Morcos, Peter N, Mok, Tony

“…Alectinib, a potent ALK tyrosine kinase inhibitor, was more effective and somewhat less toxic than crizotinib when used as primary therapy in patients with ALK…”
Get full text

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C by Yaeger, Rona, Weiss, Jared, Pelster, Meredith S., Spira, Alexander I., Barve, Minal, Ou, Sai-Hong I., Leal, Ticiana A., Bekaii-Saab, Tanios S., Paweletz, Cloud P., Heavey, Grace A., Christensen, James G., Velastegui, Karen, Kheoh, Thian, Der-Torossian, Hirak, Klempner, Samuel J.

“…In heavily pretreated patients with mutant KRAS G12C colorectal cancer, adagrasib induced a response in 19% as single agent and in 46% in combination with…”
Get full text

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial by Shaw, Alice T, Solomon, Benjamin J, Chiari, Rita, Riely, Gregory J, Besse, Benjamin, Soo, Ross A, Kao, Steven, Lin, Chia-Chi, Bauer, Todd M, Clancy, Jill S, Thurm, Holger, Martini, Jean-Francois, Peltz, Gerson, Abbattista, Antonello, Li, Sherry, Ou, Sai-Hong Ignatius

“…Lorlatinib is a potent, brain-penetrant, third-generation tyrosine kinase inhibitor (TKI) that targets ALK and ROS1 with preclinical activity against most…”
Get full text

KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne? by Nagasaka, Misako, Li, Yiwei, Sukari, Ammar, Ou, Sai-Hong Ignatius, Al-Hallak, Mohammed Najeeb, Azmi, Asfar S.

“…•Mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) are common in cancer.•KRAS remains a challenging therapeutic target.•Recently, several novel…”
Get full text

Targeting MET in Lung Cancer: Will Expectations Finally Be MET? by Drilon, Alexander, Cappuzzo, Federico, Ou, Sai-Hong Ignatius, Camidge, D Ross

“…The hepatocyte growth factor receptor (MET) is a potential therapeutic target in a number of cancers, including NSCLC. In NSCLC, MET pathway activation is…”
Get more information

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 by Yang, James C-H, Prof, Sequist, Lecia V, MD, Geater, Sarayut Lucien, MD, Tsai, Chun-Ming, Prof, Mok, Tony Shu Kam, Prof, Schuler, Martin, Prof, Yamamoto, Nobuyuki, Prof, Yu, Chong-Jen, Prof, Ou, Sai-Hong I, MD, Zhou, Caicun, Prof, Massey, Daniel, MSc, Zazulina, Victoria, MD, Wu, Yi-Long, Prof

“…Summary Background Most patients with non-small-cell lung cancer tumours that have EGFR mutations have deletion mutations in exon 19 or the Leu858Arg point…”
Get full text

Landscape of Acquired Resistance to Osimertinib in EGFR -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion by Piotrowska, Zofia, Isozaki, Hideko, Lennerz, Jochen K, Gainor, Justin F, Lennes, Inga T, Zhu, Viola W, Marcoux, Nicolas, Banwait, Mandeep K, Digumarthy, Subba R, Su, Wenjia, Yoda, Satoshi, Riley, Amanda K, Nangia, Varuna, Lin, Jessica J, Nagy, Rebecca J, Lanman, Richard B, Dias-Santagata, Dora, Mino-Kenudson, Mari, Iafrate, A John, Heist, Rebecca S, Shaw, Alice T, Evans, Erica K, Clifford, Corinne, Ou, Sai-Hong I, Wolf, Beni, Hata, Aaron N, Sequist, Lecia V

“…We present a cohort of 41 patients with osimertinib resistance biopsies, including 2 with an acquired fusion. Although fusions have been identified in…”
Get more information

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study by Solomon, Benjamin J, Besse, Benjamin, Bauer, Todd M, Felip, Enriqueta, Soo, Ross A, Camidge, D Ross, Chiari, Rita, Bearz, Alessandra, Lin, Chia-Chi, Gadgeel, Shirish M, Riely, Gregory J, Tan, Eng Huat, Seto, Takashi, James, Leonard P, Clancy, Jill S, Abbattista, Antonello, Martini, Jean-François, Chen, Joseph, Peltz, Gerson, Thurm, Holger, Ou, Sai-Hong Ignatius, Shaw, Alice T

“…Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of ALK and ROS1 tyrosine kinases with broad coverage of ALK mutations. In a phase 1 study,…”
Get full text

Alectinib in ALK -positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial by Shaw, Alice T, Dr, Gandhi, Leena, MD, Gadgeel, Shirish, Prof, Riely, Gregory J, MD, Cetnar, Jeremy, MD, West, Howard, MD, Camidge, D Ross, MD, Socinski, Mark A, Prof, Chiappori, Alberto, MD, Mekhail, Tarek, MD, Chao, Bo H, MD, Borghaei, Hossein, DO, Gold, Kathryn A, MD, Zeaiter, Ali, MD, Bordogna, Walter, PhD, Balas, Bogdana, MD, Puig, Oscar, PhD, Henschel, Volkmar, PhD, Ou, Sai-Hong Ignatius, Prof

“…Summary Background Alectinib—a highly selective, CNS-active, ALK inhibitor—showed promising clinical activity in crizotinib-naive and crizotinib-resistant…”
Get full text

The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the Why, the How, the Who, the Unknown, and the Inevitable by Reungwetwattana, Thanyanan, Liang, Ying, Zhu, Viola, Ou, Sai-Hong Ignatius

“…Highlights • METex14 alterations occur in 2–3% of lung cancers. • MET TKIs have shown preliminary clinical benefit in patients with METex14+ NSCLC. • Targeting…”
Get full text

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers by BERGETHON, Kristin, SHAW, Alice T, MARK, Eugene J, BATTEN, Julie M, HAIQUAN CHEN, WILNER, Keith D, KWAK, Eunice L, CLARK, Jeffrey W, CARBONE, David P, HONGBIN JI, ENGELMAN, Jeffrey A, MINO-KENUDSON, Mari, IGNATIUS OU, Sai-Hong, PAO, William, IAFRATE, A. John, KATAYAMA, Ryohei, LOVLY, Christine M, MCDONALD, Nerina T, MASSION, Pierre P, SIWAK-TAPP, Christina, GONZALEZ, Adriana, RONG FANG

“…Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase gene have recently been described in a subset of non-small-cell lung cancers (NSCLCs)…”
Get full text

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer by Hrustanovic, Gorjan, Olivas, Victor, Pazarentzos, Evangelos, Tulpule, Asmin, Asthana, Saurabh, Blakely, Collin M, Okimoto, Ross A, Lin, Luping, Neel, Dana S, Sabnis, Amit, Flanagan, Jennifer, Chan, Elton, Varella-Garcia, Marileila, Aisner, Dara L, Vaishnavi, Aria, Ou, Sai-Hong I, Collisson, Eric A, Ichihara, Eiki, Mack, Philip C, Lovly, Christine M, Karachaliou, Niki, Rosell, Rafael, Riess, Jonathan W, Doebele, Robert C, Bivona, Trever G

“…Unraveling the signaling dependencies of EMLK4-ALK fusion–driven lung cancer reveals upfront combination therapy strategies. One strategy for combating…”
Get full text

Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence by Ou, Sai-Hong Ignatius

“…Highlights ► The development of reversible EGFR inhibitors was a critical step in NSCLC therapy. ► Recently, irreversible and/or multitargeted inhibitors have…”
Get full text

Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC by Nagasaka, Misako, Ou, Sai-Hong Ignatius

Get more information

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases by Costa, Daniel B, Shaw, Alice T, Ou, Sai-Hong I, Solomon, Benjamin J, Riely, Gregory J, Ahn, Myung-Ju, Zhou, Caicun, Shreeve, S Martin, Selaru, Paulina, Polli, Anna, Schnell, Patrick, Wilner, Keith D, Wiltshire, Robin, Camidge, D Ross, Crinò, Lucio

“…Crizotinib is an oral kinase inhibitor approved for the treatment of ALK-rearranged non-small-cell lung cancer (NSCLC). The clinical benefits of crizotinib in…”
Get full text

Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK -Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study by Solomon, Benjamin J, Bauer, Todd M, Ignatius Ou, Sai-Hong, Liu, Geoffrey, Hayashi, Hidetoshi, Bearz, Alessandra, Penkov, Konstantin, Wu, Yi-Long, Arrieta, Oscar, Jassem, Jacek, Calella, Anna M, Peltz, Gerson, Polli, Anna, Thurm, Holger, Mok, Tony

“…Lorlatinib significantly improved progression-free survival (PFS) versus crizotinib and showed robust intracranial activity in patients with previously…”
Get full text

High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression by Ou, Sai-Hong Ignatius, Agarwal, Nikita, Ali, Siraj M.

“…•MET amplification as resistance to osimertinib.•Crizotinib provided temporary symptom relief.•Combination of Osiemrtinib+MET inhibitor should be investigated…”
Get full text

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer by Shaw, Alice T, Solomon, Benjamin J, Besse, Benjamin, Bauer, Todd M, Lin, Chia-Chi, Soo, Ross A, Riely, Gregory J, Ou, Sai-Hong Ignatius, Clancy, Jill S, Li, Sherry, Abbattista, Antonello, Thurm, Holger, Satouchi, Miyako, Camidge, D Ross, Kao, Steven, Chiari, Rita, Gadgeel, Shirish M, Felip, Enriqueta, Martini, Jean-François

“…Lorlatinib is a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK)/ROS1 tyrosine kinase inhibitor (TKI) with robust clinical activity…”
Get full text

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial by Jänne, Pasi A, Dr Prof, Ou, Sai-Hong I, MD, Kim, Dong-Wan, MD, Oxnard, Geoffrey R, MD, Martins, Renato, Prof, Kris, Mark G, Prof, Dunphy, Frank, Prof, Nishio, Makoto, MD, O'Connell, Joseph, MD, Paweletz, Cloud, PhD, Taylor, Ian, PhD, Zhang, Hui, PhD, Goldberg, Zelanna, MD, Mok, Tony, Prof

“…Summary Background Patients with EGFR -mutant non-small-cell lung cancer generally have a progression-free survival of 9–13 months while being treated with the…”
Get full text

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer by Farago, Anna F, Le, Long P, Zheng, Zongli, Muzikansky, Alona, Drilon, Alexander, Patel, Manish, Bauer, Todd M, Liu, Stephen V, Ou, Sai-Hong I, Jackman, David, Costa, Daniel B, Multani, Pratik S, Li, Gary G, Hornby, Zachary, Chow-Maneval, Edna, Luo, David, Lim, Jonathan E, Iafrate, Anthony J, Shaw, Alice T

“…Chromosomal rearrangements involving neurotrophic tyrosine kinase 1 (NTRK1) occur in a subset of non-small cell lung cancers (NSCLCs) and other solid tumor…”
Get more information